Vemurafenib pharmacokinetics and its correlation with efficacy and safety in outpatients with advanced BRAF-mutated melanoma

被引：40

作者：

Kramkimel, N. ^{[1
]}

Thomas-Schoemann, A. ^{[2
,3
,4
]}

Sakji, L. ^{[5
]}

Golmard, J. L. ^{[6
]}

Noe, G. ^{[3
]}

Regnier-Rosencher, E. ^{[1
]}

Chapuis, N. ^{[7
]}

Maubec, E. ^{[8
]}

Vidal, M. ^{[2
,3
,4
]}

Avril, M. F. ^{[1
,9
]}

Goldwasser, F. ^{[2
,9
,10
]}

Mortier, L. ^{[11
]}

Dupin, N. ^{[1
,9
]}

Blanchet, B. ^{[2
,3
]}

机构：

[1] Hop Cochin, AP HP, Dept Dermatol, 27 Rue Faubourg St Jacques, F-75674 Paris, France

[2] Ctr Etude & Recours Inhibiteurs Langiogenese CERI, Paris, France

[3] Hop Cochin, AP HP, Unite Fonct Pharmacocinet & Pharmacochim, 27 Rue Faubourg St Jacques, F-75014 Paris, France

[4] Univ Paris 05, PRES Sorbonne Paris Cite, UFR Pharm, CNRS UMR8638, Paris, France

[5] CHRU Lille, Serv Dermatol, Paris, France

[6] Hop La Pitie Salpetriere, AP HP, Dept Biostat, Paris, France

[7] Hop Cochin, AP HP, Serv Hematol Biol, 27 Rue Faubourg St Jacques, F-75674 Paris, France

[8] Hop Bichat Claude Bernard, AP HP, Dept Dermatol, F-75877 Paris, France

[9] Univ Paris 05, PRES Sorbonne Paris Cite, Fac Med, Inst Cochin,CNRS,INSERM,Unite Mixte Rech 8104,U10, Paris, France

[10] Hop Cochin, AP HP, Serv Canc Med, 27 Rue Faubourg St Jacques, F-75674 Paris, France

[11] Univ Lille 2, Fac Med, INSERM U 837, Lille, France

来源：

TARGETED ONCOLOGY | 2016年 / 11卷 / 01期

关键词：

JAPANESE PATIENTS; ERLOTINIB; CANCER; RASH; SORAFENIB; DECREASES; SURVIVAL; PLASMA; RAF;

D O I：

10.1007/s11523-015-0375-8

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Vemurafenib is a BRAF kinase inhibitor approved for first-line treatment of metastatic BRAF (V600) -mutant melanoma. However, data on the pharmacokinetic/pharmacodynamic (PK/PD) relationship are lacking. The aim of this prospective, multicenter study was to explore the PK/PD relationship for vemurafenib in outpatients with advanced BRAF-mutated melanoma. Fifty-nine patients treated with single-agent vemurafenib were prospectively analyzed. Vemurafenib plasma concentration (n = 159) was measured at days 15, 30, 60, and 90 after treatment initiation. Clinical and biological determinants (including plasma vemurafenib concentration) for efficacy and safety were assessed using Cox's model and multivariate stepwise logistic regression. Median progression-free survival (PFS) and overall survival were 5.0 (95 % confidence interval [95 % CI] 2.0-6.0) and 11.0 (95% CI 7.0-16.0) months, respectively. Twenty-nine patients (49 %) experienced any grade a parts per thousand yen3 toxicity and the most frequent grade a parts per thousand yen2 toxicity was skin rash (37 %). Severe toxicities led to definitive discontinuation in seven patients (12 %). Grade a parts per thousand yen2 skin rash was not statistically associated with better objective response at day 60 (p = 0.06) and longer PFS (hazard ratio 0.47; 95 % CI 0.21-1.08; p = 0.075). Grade a parts per thousand yen2 skin rash was statistically increased in patients with ECOG a parts per thousand yenaEuro parts per thousand 1 (odds ratio 4.67; 95 % CI 1.39-15.70; p = 0.012). Vemurafenib concentration below 40.4 mg/L at day 15 was significantly associated with a shorter PFS (1.5 [0.5-5.5] vs. 4.5 [2-undetermined] months, p = 0.029). Finally, vemurafenib concentration was significantly greater in patients developing grade a parts per thousand yen2 rash (61.7 +/- 25.0 vs. 36.3 +/- 17.9 mg/L, p < 0.0001). These results suggest that early plasma drug monitoring may help identify outpatients at high risk of non-response or grade a parts per thousand yenaEuro parts per thousand 2 skin rash.

引用

页码：59 / 69

页数：11

共 28 条

[11]

Gey A, 2014, J EUR ACAD DERMATOL

[12] Predictive and prognostic factors in second- and third-line erlotinib treatment in NSCLC patients with known status of the EGFR gene [J].

Krawczyk, Pawel ;

Kowalski, Dariusz M. ;

Krawczyk, Kamila Wojas ;

Szczyrek, Michal ;

Mlak, Radoslaw ;

Rolski, Andrzej ;

Szudy, Aneta ;

Kieszko, Robert ;

Winiarczyk, Kinga ;

Milanowski, Janusz ;

Krzakowski, Maciej .

ONCOLOGY REPORTS, 2013, 30 (03) :1463-1472

[13] Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study [J].

Larkin, James ;

Del Vecchio, Michele ;

Ascierto, Paolo A. ;

Krajsova, Ivana ;

Schachter, Jacob ;

Neyns, Bart ;

Espinosa, Enrique ;

Garbe, Claus ;

Sileni, Vanna Chiarion ;

Gogas, Helen ;

Miller, Wilson H., Jr. ;

Mandala, Mario ;

Hospers, Geke A. P. ;

Arance, Ana ;

Queirolo, Paola ;

Hauschild, Axel ;

Brown, Michael P. ;

Mitchell, Lada ;

Veronese, Luisa ;

Blank, Christian U. .

LANCET ONCOLOGY, 2014, 15 (04) :436-444

[14] Acute Renal Failure Associated With the New BRAF Inhibitor Vemurafenib [J].

Launay-Vacher, Vincent ;

Zimner-Rapuch, Sarah ;

Poulalhon, Nicolas ;

Fraisse, Thibault ;

Garrigue, Valerie ;

Gosselin, Morgane ;

Amet, Sabine ;

Janus, Nicolas ;

Deray, Gilbert .

CANCER, 2014, 120 (14) :2158-2163

[15] Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study [J].

McArthur, Grant A. ;

Chapman, Paul B. ;

Robert, Caroline ;

Larkin, James ;

Haanen, John B. ;

Dummer, Reinhard ;

Ribas, Antoni ;

Hogg, David ;

Hamid, Omid ;

Ascierto, Paolo A. ;

Garbe, Claus ;

Testori, Alessandro ;

Maio, Michele ;

Lorigan, Paul ;

Lebbe, Celeste ;

Jouary, Thomas ;

Schadendorf, Dirk ;

O'Day, Stephen J. ;

Kirkwood, John M. ;

Eggermont, Alexander M. ;

Dreno, Brigitte ;

Sosman, Jefferey A. ;

Flaherty, Keith T. ;

Yin, Ming ;

Caro, Ivor ;

Cheng, Suzanne ;

Trunzer, Kerstin ;

Hauschild, Axel .

LANCET ONCOLOGY, 2014, 15 (03) :323-332

[16] Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients [J].

Narjoz, C. ;

Cessot, A. ;

Thomas-Schoemann, A. ;

Golmard, J. L. ;

Huillard, O. ;

Boudou-Rouquette, P. ;

Behouche, A. ;

Taieb, F. ;

Durand, J. P. ;

Dauphin, A. ;

Coriat, R. ;

Vidal, M. ;

Tod, M. ;

Alexandre, J. ;

Loriot, M. A. ;

Goldwasser, F. ;

Blanchet, B. .

INVESTIGATIONAL NEW DRUGS, 2015, 33 (01) :257-268

[17] Erlotinib: Another Candidate for the Therapeutic Drug Monitoring of Targeted Therapy of Cancer? A Pharmacokinetic and Pharmacodynamic Systematic Review of Literature [J].

Petit-Jean, Emilie ;

Buclin, Thierry ;

Guidi, Monia ;

Quoix, Elisabeth ;

Gourieux, Benedicte ;

Decosterd, Laurent A. ;

Gairard-Dory, Anne-Cecile ;

Ubeaud-Sequier, Genevieve ;

Widmer, Nicolas .

THERAPEUTIC DRUG MONITORING, 2015, 37 (01) :2-21

[18] Acute kidney injury in patients with severe rash on vemurafenib treatment for metastatic melanomas [J].

Regnier-Rosencher, E. ;

Lazareth, H. ;

Gressier, L. ;

Avril, M. F. ;

Thervet, E. ;

Dupin, N. .

BRITISH JOURNAL OF DERMATOLOGY, 2013, 169 (04) :934-938

[19] Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma [J].

Schilling, B. ;

Sondermann, W. ;

Zhao, F. ;

Griewank, K. G. ;

Livingstone, E. ;

Sucker, A. ;

Zelba, H. ;

Weide, B. ;

Trefzer, U. ;

Wilhelm, T. ;

Loquai, C. ;

Berking, C. ;

Hassel, J. ;

Kahler, K. C. ;

Utikal, J. ;

Al Ghazal, P. ;

Gutzmer, R. ;

Goldinger, S. M. ;

Zimmer, L. ;

Paschen, A. ;

Hillen, U. ;

Schadendorf, D. .

ANNALS OF ONCOLOGY, 2014, 25 (03) :747-753

[20] Survival in BRAF V600-Mutant Advanced Melanoma Treated with Vemurafenib [J].

Sosman, Jeffrey A. ;

Kim, Kevin B. ;

Schuchter, Lynn ;

Gonzalez, Rene ;

Pavlick, Anna C. ;

Weber, Jeffrey S. ;

McArthur, Grant A. ;

Hutson, Thomas E. ;

Moschos, Stergios J. ;

Flaherty, Keith T. ;

Hersey, Peter ;

Kefford, Richard ;

Lawrence, Donald ;

Puzanov, Igor ;

Lewis, Karl D. ;

Amaravadi, Ravi K. ;

Chmielowski, Bartosz ;

Lawrence, H. Jeffrey ;

Shyr, Yu ;

Ye, Fei ;

Li, Jiang ;

Nolop, Keith B. ;

Lee, Richard J. ;

Joe, Andrew K. ;

Ribas, Antoni .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (08) :707-714

← 1 2 3 →